Abstract
ANCA-associated vasculitis (AAV) belongs to a group of small vessel systemic vasculitides characterized by granulomatous and neutrophilic inflammation of various tissues. Patients often have circulating autoantibodies targeting neutrophilic antigens. Although AAV was once associated with severe end-organ damage and extremely high mortality rates, the use of glucocorticoids and cyclophosphamide led to a paradigm change in its treatment. Over the past 20 years, significant progress in understanding the immunopathogenesis of AAV has enabled development of targeted immunotherapies, providing a much better prognosis for patients. This review describes the evolution of treatment of AAV, particularly for patients with kidney involvement.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Psychiatry and Mental health,Neuropsychology and Physiological Psychology
Reference82 articles.
1. On a hitherto undescribed peculiar arterial disease (periarteritis nodosa), which is associated with Morbus Brightii and rapidly progressing general muscle paralysis;Kussmaul;Distch Arch Klin Med.,1866
2. Historical perspective of vasculitis;Matteson;Curr Rheumatol Rep.,2002
3. Wegener's granulomatosis;Duna;Rheum Dis Clin North Am.,1995
4. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa;Churg;Am J Pathol.,1951
5. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?;Davies;Br Med J (Clin Res Ed).,1982